Investigational Agents in the Treatment of Eosinophilic Esophagitis 
Allison Burdick, Kenedee Gallimore, John Kurth
Abstract
Eosinophilic Esophagitis (EoE) is a chronic, allergic disease of the esophagus that is characterized by increased esophageal eosinophils caused by allergens. If untreated, EoE precipitates esophageal remodeling that can lead to structural esophageal changes and difficulty eating. Although there are currently no FDA approved therapies for the treatment of EoE, therapies approved for other inflammatory conditions such as topical corticosteroids have a strong recommendation in the current guidelines. Dietary strategies are also currently being utilized, but have shown to be unfeasible in clinical experience. Although not yet approved, new
treatment options are being developed to enhance the quality of life in patients suffering from EoE. This article features novel therapeutic approaches to treating EoE, including investigational agents RPC4046, dupilumab, antolimab, and benralizumab.
Full Text
volume5article4.pdf
File Size: 699 kb
File Type: pdf
Download File

Notice and Disclaimer

Medicine is an ever-changing science.  As new research and clinical experience broaden our knowledge, changes in treatment and drug therapy are required.  The authors and the publisher of this work have checked with sources believed to be reliable in their efforts to provide information that is complete and generally in accord with the standards accepted at the time of publication.  However, in view of the possibility of human error or changes in medical sciences, neither the authors nor the publisher nor any other party who has been involved in the preparation or publication of this work warrants that the information contained herein is accurate or complete, and they disclaim all responsibility for any errors or omissions or for the results obtained from use of the information contained in this work.    Readers are encouraged to confirm the information contained herein with other sources.   For example and in particular, readers are advised to check the product information sheet included in the package of each drug they plan to administer to be certain that the information contained in this work is accurate and that changes have not been made in the recommended dose or in the contraindications for administration.

Subscribe to ARxCH